Novartis has entered into a clinical research collaboration with Bristol-Myers Squibb for a possible combo treatment for metastatic colorectal cancer.
According to the agreement, BMS will investigate the safety, tolerability, and efficacy of Novartis's Mekinist in combination with BMS’ own Opdivo and Opdivo plus Yervoy regimen.
Since its Opdivo and Yervoy combination regimen became the first immuno-oncology combination approved for the treatment of metastatic melanoma in 2015, BMS has continued to evaluate Opdivo alone or in combination therapies with Yervoy and other anti-cancer agents.
Read the Nasdaq coverage